Ambryon Biosciences

AAV6.2FF Serotype

AAV6.2 variant with dual tyrosine-to-phenylalanine mutations (Y445F+Y731F) preventing ubiquitination and enhancing transduction through improved trafficking.

TropismSkeletal muscle (enhanced), liver, cardiac muscle

Characteristics

Y445F and Y731F tyrosine mutations. Prevents ubiquitination and proteasomal degradation. Enhanced intracellular trafficking. 2-5 fold improved transduction versus AAV6.2. Reduced vector dose requirements.

Applications

Muscular dystrophy gene therapy. Liver-directed applications requiring lower vector doses. Enhanced efficiency applications.

Sequence1 bp

Sign in to view the full sequence.

Sign in

References

  1. 1.Rutledge et al. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J Virol — Rutledge 1998 AAV6

Identifiers & revision